Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells
- 27 June 2018
- journal article
- research article
- Published by Springer Nature in The AAPS Journal
- Vol. 20 (5) , 1-15
Abstract
The pharmacodynamic interactions among trifluoperazine (TFP), gemcitabine (GEM), and paclitaxel (PTX) were assessed in pancreatic cancer cells (PANC-1). ThKeywords
This publication has 48 references indexed in Scilit:
- Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancerOncotarget, 2015
- Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in miceCancer Chemotherapy and Pharmacology, 2013
- Trifluoperazine, an Antipsychotic Agent, Inhibits Cancer Stem Cell Growth and Overcomes Drug Resistance of Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of schedulingInternational Journal of Oncology, 2008
- Investigation of the pharmacokinetics of gemcitabine and 2′,2′-difluorodeoxyuridine in human plasma by liquid chromatographyAnalytical Biochemistry, 2004
- Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell linesBritish Journal of Cancer, 2000
- Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines.International Journal of Oncology, 1998
- Cell cycle G2/M arrest and activation of cyclin-dependent kinases associated with low-dose paclitaxel-induced sub-G1 apoptosisApoptosis, 1997
- COMPARISON OF THE EFFICACY OF A PHENOTHIAZINE AND A BISQUINALDINIUM CALMODULIN ANTAGONIST AGAINST MULTIDRUG-RESISTANT P388 CELL-LINES1990
- AFFINITY, INTRINSIC ACTIVITY AND DRUG INTERACTIONSPharmacological Reviews, 1957